We are live on
!
Find out more
IHAM
Integral Health Asset Management Portfolio holdings
AUM
$2.09B
1-Year Est. Return
112.84%
This Fund
S&P 500
This Quarter
Est. Return
-3.11%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$722M
AUM Growth
-$85.3M
(-11%)
Cap. Flow
-$23.1M
Cap. Flow
% of AUM
-3.19%
Top 10 Holdings %
Top 10 Hldgs %
36.06%
Holding
97
New
24
Increased
24
Reduced
14
Closed
32
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tenet Healthcare
THC
|
+$23M |
| 2 |
DexCom
DXCM
|
+$19.7M |
| 3 |
Medtronic
MDT
|
+$18.4M |
| 4 |
Becton Dickinson
BDX
|
+$17.6M |
| 5 |
Amgen
AMGN
|
+$16.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$34.2M |
| 2 |
Zimmer Biomet
ZBH
|
+$29.2M |
| 3 |
Cooper Companies
COO
|
+$13.6M |
| 4 |
Centene
CNC
|
+$13.5M |
| 5 |
AbbVie
ABBV
|
+$13.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.17% |
| 2 | Consumer Discretionary | 0.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AKRO
51
DELISTED
Akero Therapeutics
AKRO
| $5.06M | 0.7% |
100,000
+30,000
| +43% | +$1.4M |
|
52
Cabaletta Bio
CABA
$458M
| $5.02M | 0.7% |
+330,000
| New | +$4.51M |
|
53
Pfizer
PFE
$150B
| $4.98M | 0.69% |
+150,000
| New | +$5.3M |
|
|
54
Cooper Companies
COO
$14.7B
| $4.77M | 0.66% |
60,000
-148,000
| -71% | -$13.6M |
|
55
Replimune Group
REPL
$1.29B
| $4.28M | 0.59% |
250,000
-195,000
| -44% | -$3.83M |
|
|
LBPH
56
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $4.23M | 0.59% |
760,000
+162,000
| +27% | +$1.04M |
|
57
Envista
NVST
$4.57B
| $4.18M | 0.58% |
150,000
| – | – |
|
58
Zoetis
ZTS
$30B
| $3.48M | 0.48% |
+20,000
| New | +$3.63M |
|
|
ETNB
59
CALL
DELISTED
89bio
ETNB
| $3.09M | 0.43% |
+200,000
| New | +$3.36M |
|
|
WW
60
DELISTED
WW International
WW
| $2.77M | 0.38% |
+250,000
| New | +$2.46M |
|
61
Tandem Diabetes Care
TNDM
$1.6B
| $2.7M | 0.37% |
+130,000
| New | +$3.57M |
|
|
BPMC
62
DELISTED
Blueprint Medicines
BPMC
| $2.51M | 0.35% |
+50,000
| New | +$2.67M |
|
63
HCA Healthcare
HCA
$88.5B
| $2.46M | 0.34% |
10,000
-30,000
| -75% | -$8.21M |
|
|
SILK
64
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $2.25M | 0.31% |
+150,000
| New | +$3.12M |
|
|
RVNC
65
DELISTED
Revance Therapeutics, Inc.
RVNC
| $1.15M | 0.16% |
100,000
-150,000
| -60% | -$2.88M |
|
|
66
AbbVie
ABBV
$441B
| – | – |
-100,000
| Closed | -$13.5M |
|
67
Allogene Therapeutics
ALLO
$725M
| – | – |
-412,000
| Closed | -$2.05M |
|
68
Alnylam Pharmaceuticals
ALNY
$29.9B
| – | – |
-52,000
| Closed | -$9.88M |
|
|
APLS
69
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-72,000
| Closed | -$6.56M |
|
70
BioMarin Pharmaceuticals
BMRN
$13.7B
| – | – |
-50,000
| Closed | -$4.33M |
|
71
BioNTech
BNTX
$23.4B
| – | – |
-36,000
| Closed | -$3.89M |
|
|
CCRN
72
DELISTED
Cross Country Healthcare
CCRN
| – | – |
-155,000
| Closed | -$4.35M |
|
|
73
Centene
CNC
$32.9B
| – | – |
-200,000
| Closed | -$13.5M |
|
74
Danaher
DHR
$144B
| – | – |
-56,400
| Closed | -$12M |
|
75
Dyne Therapeutics
DYN
$5.03B
| – | – |
-62,000
| Closed | -$698K |
|
Similar funds
CL
ACM
ACG
NSUP
TP
ACP
TA
AG
Integral Health Asset Management's Q3 2023 Portfolio in Review
As of Q3 2023, Integral Health Asset Management held 97 positions worth $722M, down 11% from $808M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Integral Health Asset Management withdrew a net $23.1M in Q3 2023, closing 32 positions and reducing 14 holdings. Its most notable exit was Centene, an estimated $13.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 94% a quarter earlier, followed by Consumer Discretionary.
Against the trend, Integral Health Asset Management opened a new position in DexCom worth $16.3M.
- Integral Health Asset Management's largest Q3 2023 buy was DexCom: 175,000 shares worth $16.3M.
- Integral Health Asset Management added most to Tenet Healthcare in Q3 2023, an estimated $23M increase.
- Integral Health Asset Management's biggest Q3 2023 reduction was Cigna, cutting an estimated $34.2M.
- Integral Health Asset Management fully exited Centene in Q3 2023, selling an estimated $13.5M.
- Integral Health Asset Management's ten largest holdings make up 36% of its $722M portfolio in Q3 2023.
- Integral Health Asset Management opened 24 new positions and closed 32 in Q3 2023.
- Integral Health Asset Management's portfolio value fell 11% quarter-over-quarter to $722M.
Based on Integral Health Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.